MORPHABOND ER Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Morphabond Er patents expire, and what generic alternatives are available?
Morphabond Er is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-three patent family members in ten countries.
The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Morphabond Er
A generic version of MORPHABOND ER was approved as morphine sulfate by HOSPIRA on May 11th, 1988.
Summary for MORPHABOND ER
International Patents: | 23 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Patent Applications: | 3,534 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for MORPHABOND ER |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MORPHABOND ER |
DailyMed Link: | MORPHABOND ER at DailyMed |


Anatomical Therapeutic Chemical (ATC) Classes for MORPHABOND ER
Paragraph IV (Patent) Challenges for MORPHABOND ER
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MORPHABOND ER | Extended-release Tablets | morphine sulfate | 15 mg, 30 mg, 60 mg and 100 mg | 206544 | 1 | 2019-01-28 |
US Patents and Regulatory Information for MORPHABOND ER
MORPHABOND ER is protected by two US patents.
Patents protecting MORPHABOND ER
Pharmaceutical compositions configured to deter dosage form splitting
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Abuse resistant drugs, method of use and method of making
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-001 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-004 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-002 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-004 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-001 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MORPHABOND ER
See the table below for patents covering MORPHABOND ER around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2017200414 | Abuse resistant drugs, method of use and method of making | ⤷ Try a Trial |
Japan | 6608319 | ⤷ Try a Trial | |
Australia | 2009282376 | Pharmaceutical compositions configured to deter dosage form splitting | ⤷ Try a Trial |
Poland | 2187873 | ⤷ Try a Trial | |
Canada | 2696341 | MEDICAMENTS RESISTANT AUX ABUS, PROCEDES D'UTILISATION ET DE FABRICATION (ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |